CoChat
Sign Up
Cited by 152Treatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorStress Responses and Cortisol

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression

Nickel, Thomas, Sonntag, Annette, Schill, Julia, Zobel, Astrid W., Ackl, Nibal, Brunnauer, Alexander, Murck, Harald, Ising, Marcus, Yassouridis, Alexander, Steiger, Axel, Zihl, Josef, Holsboer, Florian·2003·Journal of Clinical Psychopharmacology
DOI 10.1097/00004714-200304000-00008
Open this paper in CoChat — free account

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used as effective pharmacological agents to treat depressive disorders. In contrast to the SSRIs, which block the presynaptic serotonin (5-HT) transporter and by this route increase the concentration of serotonin in the synaptic cleft, the antidepressant tianeptine enhances the presynaptic neuronal reuptake of 5-HT and thus decreases serotonergic neurotransmission. Both SSRIs and tianeptine are clinically effective; however, their opposite modes of action challenge the prevailing concepts on the need of enhancement of serotonergic neurotransmission. To better understand the differences between these two opposite pharmacological modes of action, we compared the changes induced by tianeptine and paroxetine on psychopathology, the hypothalamic-pituitary-adrenocortical (HPA) system, and cognitive functions in a double-blind, randomized, controlled trial including 44 depressed inpatients over a period of 42 days. Depressive symptomatology significantly improved in all efficacy measures, with no significant differences between tianeptine and paroxetine. There was a trend toward better response to the SSRI among women. Assessment of the HPA system showed marked hyperactivity before the beginning of treatment, which then normalized in most of the patients, without significant differences between the two antidepressants. Cognitive assessments showed no significant differences between the two drugs investigated. The results of…

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-200304000-00008

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 70 references

Research works printed but not linked: 8

  1. Sulser, 1987, J Clin Psychiatry, 48, 12
  2. van Praag, 1982, Adv Biochem Psychopharmacol, 34, 259
  3. Owens, 1997, J Pharmacol Exp Ther, 283, 1305
  4. Kato, 1988, Clin Neuropharmacol, 11, 43
  5. Mennini, 1991, Presse Med, 20, 1823
  6. Szádóczky, 2000, Neuropsychopharmacologia Hungarica, 2, 171
  7. Reul, 1993, Endocrinology, 133, 312, 10.1210/en.133.1.312 · DOI
  8. Nebes, 1999, J Clin Psychiatry, 60, 26

Cited by

Sorted by citations

See all 152

Related

Metadata

Authors
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., Zihl, J., & Holsboer, F.
Affiliations
Max Planck Institute of Psychiatry (DE)
ORCID
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-04
Volume
23
Issue
2
Pages
155-168
ISSN
0271-0749 (ISSN-L)
DOI
10.1097/00004714-200304000-00008
OpenAlex
W2085339275
Cited by
152
References
70
Citations by year
2025: 4 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 12 · 2013: 9 · 2012: 2
FWCI
8.14
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Max Planck Institute for Plasma Physics (submittedVersion)
Funders
Servier
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
tianeptine, paroxetine, major depressive disorder, selective serotonin reuptake inhibitors, serotonin uptake, serotonergic neurotransmission, hypothalamic-pituitary-adrenal axis, cognitive function, antidepressant mechanism, inpatient depression
MeSH terms
Adult, Aged, Antidepressive Agents, Tricyclic, Cognition, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Psychometrics, Task Performance and Analysis, Thiazepines, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review